Quote:

---

Shareholder Alert: Rise of Coronavirus Variants

Innovation Pharmaceuticals (IPIX) posted today an update to its website, linked below, discussing the emergence of new coronavirus variants, which are raising concerns among scientists and public health officials worldwide. Early data suggests these variants might lessen vaccine efficacy and potentially even escape the body’s immune response.

http://www.ipharminc.com/new-blog/2021/1/20/t...une-escape

This worrisome situation illustrates a large, and likely prolonged, unmet need for COVID-19 therapeutics to supplement the use of vaccines, as the coronavirus continues to evolve and adapt. Innovation will be initiating a Phase 2, randomized, placebo-controlled clinical trial, enrolling hospitalized patients with moderate-to-severe COVID-19, to further evaluate Brilacidin’s COVID-19 treatment potential.

---